A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic

Hydroxyurea is one of the earliest drugs that showed promise in the management of haemoglobinopathies that include β-thalassaemia and sickle cell disease. Despite this, many aspects of hydroxyurea are either u...

Source: Orphanet Journal of Rare Diseases - March 1, 2021 Category: Internal Medicine Authors: Nirmani Yasara, Anuja Premawardhena and Sachith Mettananda Tags: Review Source Type: research